The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine
Open accessAbstract
The leading malaria vaccine in development is the circumsporozoite protein (CSP)-based particle vaccine, RTS,S, which targets the pre-erythrocytic stage of Plasmodium falciparum infection. It induces modest levels of protective efficacy, thought to be mediated primarily by CSP-specific antibodies. We aimed to enhance vaccine efficacy by generating a more immunogenic CSP-based particle vaccine and therefore developed a next-generation RTS,S-like vaccine, called R21. The major improvement is that in contrast to RTS,S, R21 particles are formed from a single CSP-hepatitis B surface antigen (HBsAg) fusion protein, and this leads to a vaccine composed of a much higher proportion of CSP than in RTS,S. We demonstrate that in BALB/c mice R21 is immunogenic at very low doses and when administered with the adjuvants Abisco-100 and Matrix-M it elicits sterile protection against transgenic sporozoite challenge. Concurrent induction of potent cellular and humoral immune responses was also achieved by combining R21 with TRAP-based viral vectors and protective efficacy was significantly enhanced. In addition, in contrast to RTS,S, only a minimal antibody response to the HBsAg carrier was induced. These studies identify an anti-sporozoite vaccine component that may improve upon the current leading malaria vaccine RTS,S. R21 is now under evaluation in Phase 1/2a clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Ahmad, M., Hirz, M., Pichler, H., & Schwab, H. (2014) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-014-5732-5 · Cited by 989
Recombinant protein expression in Pichia pastoris
Cregg, J. M., Cereghino, J. L., Shi, J., & Higgins, D. R. (2000) · Molecular Biotechnology · doi:10.1385/mb:16:1:23 · Cited by 927
Synthesis and assembly of hepatitis B virus surface antigen particles in yeast
Valenzuela, P., Medina, A., Rutter, W. J., Ammerer, G., & Hall, B. D. (1982) · Nature · doi:10.1038/298347a0 · Cited by 877
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
Seder, R. A., Chang, L.-J., Enama, M. E., Zephir, K. L., Sarwar, U. N., Gordon, I. J., Holman, L. A., James, E. R., Billingsley, P. F., Gunasekera, A., et al. (2013) · Science · doi:10.1126/science.1241800 · Cited by 761
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
The Influence of Antigen Organization on B Cell Responsiveness
Bachmann, M. F., Rohrer, U. H., Kündig, T. M., Bürki, K., Hengartner, H., & Zinkernagel, R. M. (1993) · Science · doi:10.1126/science.8248784 · Cited by 717
Hoffman, S. L., Goh, L. M. L., Luke, T. C., Schneider, I., Le, T. P., Doolan, D. L., Sacci, J., de la Vega, P., Dowler, M., Paul, C., et al. (2002) · The Journal of Infectious Diseases · doi:10.1086/339409 · Cited by 688
Bache, E. B., Agnandji, S. T., Lell, B., Fernandes, J. F., Abossolo, B. P., Kabwende, A. L., Adégnika, A. A., Mordmüller, B. G., Kremsner, P. G., Loembé, M. M., et al. (2015) · The Lancet · doi:10.15496/publikation-6508 · Cited by 642
Cited by
Major findings and recent advances in virus–like particle (VLP)-based vaccines
Mohsen, M. O., Zha, L., Cabral-Miranda, G., & Bachmann, M. F. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.014 · Cited by 555
RTS,S/AS01 vaccine (Mosquirix™): an overview
Laurens, M. B. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1669415 · Cited by 491
Datoo, M. S., Natama, M. H., Somé, A., Traoré, O., Rouamba, T., Bellamy, D., Yameogo, P., Valia, D., Tegneri, M., Ouedraogo, F., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00943-0 · Cited by 452
Self-citationMarcandalli, J., Fiala, B., Ols, S., Perotti, M., de van der Schueren, W., Snijder, J., Hodge, E., Benhaim, M., Ravichandran, R., Carter, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.046 · Cited by 448
Feng, X., Xu, W., Li, Z., Song, W., Ding, J., & Chen, X. (2019) · Advanced Science · doi:10.1002/advs.201900101 · Cited by 363
Malaria Vaccines: Recent Advances and New Horizons
Draper, S. J., Sack, B. K., King, C. R., Nielsen, C. M., Rayner, J. C., Higgins, M. K., Long, C. A., & Seder, R. A. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.06.008 · Cited by 331
Virus-like particle vaccinology, from bench to bedside
Mohsen, M. O., & Bachmann, M. F. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00897-8 · Cited by 289
Protein-based antigen presentation platforms for nanoparticle vaccines
Nguyen, B., & Tolia, N. H. (2021) · npj Vaccines · doi:10.1038/s41541-021-00330-7 · Cited by 271
Malaria vaccines since 2000: progress, priorities, products
Duffy, P. E., & Patrick Gorres, J. (2020) · npj Vaccines · doi:10.1038/s41541-020-0196-3 · Cited by 266
Peptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Metadata
- Authors
- Collins, K. A., Snaith, R., Cottingham, M. G., Gilbert, S. C., & Hill, A. V. S.
- Venue
- Scientific Reports
- Published
- 2017-04-19
- Volume
- 7
- Issue
- 1
- Pages
- 46621-46621
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2605491919
- Cited by
- 253
- References
- 60
- FWCI
- 15.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.